medigraphic.com

2004, Número s2

<< Anterior Siguiente >>

Arch Cardiol Mex 2004; 74 (s2)


Tratamiento de los síndromes coronarios agudos en pacientes diabéticos o con síndrome metabólico

Eng Ceceña L

Idioma: Español
Referencias bibliográficas: 35
Paginas: 275-280
Archivo PDF: 80.91 Kb.


RESUMEN

En los pacientes con diabetes mellitus tipo 2, o con síndrome metabólico el riesgo de muerte por infarto agudo del miocardio es mayor que en la población sin dichos factores de riesgo. Debe promoverse el manejo óptimo de este grupo de pacientes y es conveniente enfatizar la terapia de reperfusión mediante intervención percutánea coronaria primaria o mediante fibrinólisis, con estricto control de la glucosa sanguínea y el uso de antiagregantes plaquetarios.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.

  2. Consenso Mexicano sobre el tratamiento integral del síndrome metabólico: Med Int Mex 2002; 18: 12-41.

  3. Grupo Cooperativo RENASICA: El Registro Nacional de los Síndromes Isquémicos Coronarios Agudos (RENASICA). Arch Cardiol Mex 2002; 72: S45-S64.

  4. Grupo Cooperativo del Consenso: Primer Consenso Mexicano sobre los Síndromes Isquémicos Coronarios Agudos sin Elevación del Segmento ST (Angina Inestable e Infarto no Q). Arch Cardiol Mex 2002; 72: S5-S44.

  5. García-Castillo A: Registro Nacional de Síndromes Coronarios Agudos II (RENASICA II). XXIII Congreso Nal. Cardiol – SMC. Monterrey, NL. 2003.

  6. Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina. J Am Coll Cardiol 2000; 36: 970-1062.

  7. Creager MA, Lüscher TF, Cosentino F, Beckman JA: Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-32.

  8. Lüscher TF, Creager MA, Beckman JA, Cosentino F: Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003; 108: 1655-61.

  9. Hurst RT, Lee RW: Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 2003; 139: 824-34.

  10. Grundy S, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO: Prevention Conference VI. Diabetes and cardiovascular disease. Executive summary. Circulation 2002; 105: 2231-9.

  11. Ghosh J, Weiss MB, Kay RH, Frishman WH: Diabetes Mellitus and coronary artery disease – Therapeutic considerations. Heart Dis 2003; 5: 119-28.

  12. Hildebrandt P: Diabetic patients and acute coronary syndromes. Eur Heart J 2001; 22: 887-8.

  13. Mak KH, Moliterno DJ, Granger CB, et al: Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997; 30: 171-9.

  14. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994; 343: 311-22.

  15. Pfeffer MA, Moye LA, Braunwald E, et al: Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA 1991; 266: 528-32.

  16. Mak KH, Moliterno DJ, Granger CB, et al: Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997; 30: 171-9.

  17. Mahaffey KW, Granger CB, Coth CA, et al: Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-1 trial. J Am Coll Cardiol 1997; 30: 1606-10.

  18. Granger CB, Califf RM, Young S, et al: Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytics agents. J Am Coll Cardiol 1993; 21: 920-5.

  19. Woodfield SL, Lundergan CF, Reiner JS, et al: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for myocardial infarction: the GUSTO-1 experience. J Am Coll Cardiol 1996; 28: 1661-9.

  20. Zarich SW, Nesto RW: Diabetic cardiomyopathy. Am Heart J 1989; 118: 1000-12.

  21. Gaxiola E, Vliestra RE, Brenner AS, et al: Diabetes and multiple stents independently double the risk of short term revascularization. J Interven Cardiol 2000; 13: 87-91.

  22. Bhaskaran A, Siegel R, Barrer B, et al: Direct infarct intervention in the diabetic: Does it really work (abstr)? J Am Coll Cardiol 1999; 33: 361A.

  23. Hasdai D, Granger CB, Srivatsa SS, et al: Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. J Am Coll Cardiol 2000; 35: 1502-12.

  24. Silva JA, Ramee SR, White CJ, et al: Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 1999; 138: 446-55.

  25. Sodi-Pallares D, Testelli MR, Fishleder BL: Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 1962; 9: 166.

  26. Mak KH, Topol E: Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000; 35: 563-8.

  27. Fath-Ordoubadi F, Keatt KJ: Glucosa-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo controlled trials. Circulation 1997; 96: 1152-6.

  28. Diaz R, et al: On behalf of the Estudios Cardiológico Latinoamérica (ECLA) glucosa-Insulin-Potassium Pilot Trial Collaborative Group. Metabolic modulation of acute myocardial infarction. Circulation 1998; 98: 2227-2234.

  29. GIPS: Preliminary results presented at 24th Annual Meeting of the European Society of Cardiology, September 2002, Munich.

  30. Malmberg K, Ryden L, Efendic S, et al: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.

  31. FRagmin and Fast Revascularization during Instability in Coronary Artery Disease Investigators: Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicentre study. Lancet 1999; 354: 708-715.

  32. Cannon CP, Weintraub WS, Demopoulos LA, et al: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-1887.

  33. Roffi M, Chew DP, Mukherjee D, et al: Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767-71.

  34. Gaxiola-López E, Eng-Ceceña L: Progresos en el tratamiento del diabético con cardiopatía isquémica. Arch Cardiol Mex 2002; 72: S69-S75.

  35. Lincoff AM. Important triad in cardiovascular medicine. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 2003; 107: 1556-9.




2020     |     www.medigraphic.com